BRPI0906495B8 - compostos derivados de indolil-piridona e composição farmacêutica - Google Patents
compostos derivados de indolil-piridona e composição farmacêuticaInfo
- Publication number
- BRPI0906495B8 BRPI0906495B8 BRPI0906495A BRPI0906495A BRPI0906495B8 BR PI0906495 B8 BRPI0906495 B8 BR PI0906495B8 BR PI0906495 A BRPI0906495 A BR PI0906495A BR PI0906495 A BRPI0906495 A BR PI0906495A BR PI0906495 B8 BRPI0906495 B8 BR PI0906495B8
- Authority
- BR
- Brazil
- Prior art keywords
- alkoxy
- hydroxy
- alkyl
- hydrogen
- optionally substituted
- Prior art date
Links
- -1 indolyl-pyridone derivative compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- NRGVEGWSRITVOR-UHFFFAOYSA-N 3-(1h-indol-2-yl)-1h-pyridin-2-one Chemical class OC1=NC=CC=C1C1=CC2=CC=CC=C2N1 NRGVEGWSRITVOR-UHFFFAOYSA-N 0.000 abstract 1
- 101150050673 CHK1 gene Proteins 0.000 abstract 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 abstract 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0801090.2 | 2008-01-22 | ||
| GBGB0801090.2A GB0801090D0 (en) | 2008-01-22 | 2008-01-22 | New chemical compounds |
| GBGB0818695.9A GB0818695D0 (en) | 2008-10-11 | 2008-10-11 | New chemical compounds |
| GB0818695.9 | 2008-10-11 | ||
| PCT/GB2009/000149 WO2009093012A1 (en) | 2008-01-22 | 2009-01-20 | Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0906495A2 BRPI0906495A2 (pt) | 2015-07-14 |
| BRPI0906495A8 BRPI0906495A8 (pt) | 2015-10-06 |
| BRPI0906495B1 BRPI0906495B1 (pt) | 2020-11-10 |
| BRPI0906495B8 true BRPI0906495B8 (pt) | 2021-05-25 |
Family
ID=40377594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906495A BRPI0906495B8 (pt) | 2008-01-22 | 2009-01-20 | compostos derivados de indolil-piridona e composição farmacêutica |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8916591B2 (https=) |
| EP (1) | EP2294065B1 (https=) |
| JP (1) | JP5386508B2 (https=) |
| CN (1) | CN101970424B (https=) |
| AU (1) | AU2009207478B2 (https=) |
| BR (1) | BRPI0906495B8 (https=) |
| CA (1) | CA2712959C (https=) |
| DK (1) | DK2294065T3 (https=) |
| EA (1) | EA021464B1 (https=) |
| ES (1) | ES2461799T3 (https=) |
| IL (1) | IL206808A (https=) |
| MX (1) | MX2010007525A (https=) |
| NZ (1) | NZ586756A (https=) |
| PL (1) | PL2294065T3 (https=) |
| PT (1) | PT2294065E (https=) |
| WO (1) | WO2009093012A1 (https=) |
| ZA (1) | ZA201005210B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2294065T3 (da) | 2008-01-22 | 2014-04-28 | Vernalis R&D Ltd | Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet |
| GB0912499D0 (en) * | 2009-07-18 | 2009-08-26 | Vernalis R&D Ltd | Indopyl-pyridone derivatives |
| JP6161537B2 (ja) | 2010-04-07 | 2017-07-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法 |
| EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| TN2017000329A1 (en) * | 2015-01-28 | 2019-01-16 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| JP7313354B2 (ja) * | 2017-12-19 | 2023-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物 |
| MA53377A (fr) * | 2018-07-24 | 2021-06-02 | Epizyme Inc | Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2 |
| US10280721B1 (en) | 2018-07-27 | 2019-05-07 | Upwing Energy, LLC | Artificial lift |
| US10253606B1 (en) | 2018-07-27 | 2019-04-09 | Upwing Energy, LLC | Artificial lift |
| US10370947B1 (en) * | 2018-07-27 | 2019-08-06 | Upwing Energy, LLC | Artificial lift |
| US10787873B2 (en) | 2018-07-27 | 2020-09-29 | Upwing Energy, LLC | Recirculation isolator for artificial lift and method of use |
| ES2985569T3 (es) * | 2018-08-24 | 2024-11-06 | Transthera Sciences Nanjing Inc | Nuevo inhibidor de derivado de quinolina |
| US11686161B2 (en) | 2018-12-28 | 2023-06-27 | Upwing Energy, Inc. | System and method of transferring power within a wellbore |
| CN112625027B (zh) * | 2019-09-24 | 2022-09-09 | 药捷安康(南京)科技股份有限公司 | 杂环衍生物及其用途 |
| US20230414624A1 (en) * | 2022-06-24 | 2023-12-28 | Enalare Therapeutics Inc. | Methods of treating neurological ventilatory insufficiency |
| CN115594634B (zh) * | 2022-10-26 | 2024-10-01 | 浙江工业大学 | 一种连续化制备4-硝基吡唑的新工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20053660B (en) * | 2001-03-28 | 2005-11-10 | Bristol Myers Squibb Co | Novel Tyrosine Kinase Inhibitors |
| BR0213562A (pt) | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| JP2006526654A (ja) | 2003-06-05 | 2006-11-24 | メルク エンド カムパニー インコーポレーテッド | 置換インドールおよび置換インドールの調製方法 |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| CA2600914A1 (en) * | 2005-01-28 | 2007-07-26 | Mark E. Fraley | Inhibitors of checkpoint kinases |
| JP2008545776A (ja) | 2005-06-11 | 2008-12-18 | ヴァーナリス アールアンドディー リミテッド | 癌および自己免疫疾患の治療における使用のためのピラゾール−置換ベンズイミダゾール誘導体 |
| EP2046330A2 (en) * | 2006-07-14 | 2009-04-15 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008025526A1 (en) * | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Indole derivatives, their manufacture and use as pharmaceutical agents |
| DK2294065T3 (da) | 2008-01-22 | 2014-04-28 | Vernalis R&D Ltd | Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet |
| MX2011012202A (es) * | 2009-05-15 | 2011-12-08 | Novartis Ag | Derivados de 5-piridin-3-il-1,3-dihidro-indol-2-ona y su uso como moduladores de a sintanasa de aldosterona y/o de cyp11b1. |
-
2009
- 2009-01-20 DK DK09704645T patent/DK2294065T3/da active
- 2009-01-20 CN CN200980103188XA patent/CN101970424B/zh not_active Expired - Fee Related
- 2009-01-20 JP JP2010543556A patent/JP5386508B2/ja not_active Expired - Fee Related
- 2009-01-20 PL PL09704645T patent/PL2294065T3/pl unknown
- 2009-01-20 CA CA2712959A patent/CA2712959C/en not_active Expired - Fee Related
- 2009-01-20 EA EA201001197A patent/EA021464B1/ru not_active IP Right Cessation
- 2009-01-20 US US12/812,791 patent/US8916591B2/en not_active Expired - Fee Related
- 2009-01-20 AU AU2009207478A patent/AU2009207478B2/en not_active Ceased
- 2009-01-20 NZ NZ586756A patent/NZ586756A/en not_active IP Right Cessation
- 2009-01-20 EP EP20090704645 patent/EP2294065B1/en not_active Not-in-force
- 2009-01-20 MX MX2010007525A patent/MX2010007525A/es active IP Right Grant
- 2009-01-20 BR BRPI0906495A patent/BRPI0906495B8/pt not_active IP Right Cessation
- 2009-01-20 PT PT09704645T patent/PT2294065E/pt unknown
- 2009-01-20 WO PCT/GB2009/000149 patent/WO2009093012A1/en not_active Ceased
- 2009-01-20 ES ES09704645T patent/ES2461799T3/es active Active
-
2010
- 2010-07-05 IL IL206808A patent/IL206808A/en active IP Right Grant
- 2010-07-21 ZA ZA2010/05210A patent/ZA201005210B/en unknown
-
2014
- 2014-11-10 US US14/536,764 patent/US9604975B2/en not_active Expired - Fee Related
-
2017
- 2017-02-08 US US15/427,457 patent/US20170298043A1/en not_active Abandoned
-
2018
- 2018-04-25 US US15/962,306 patent/US10696652B2/en not_active Expired - Fee Related
-
2020
- 2020-05-28 US US16/886,276 patent/US20200361905A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009207478A1 (en) | 2009-07-30 |
| PL2294065T3 (pl) | 2014-11-28 |
| US20170298043A1 (en) | 2017-10-19 |
| US10696652B2 (en) | 2020-06-30 |
| DK2294065T3 (da) | 2014-04-28 |
| US9604975B2 (en) | 2017-03-28 |
| PT2294065E (pt) | 2014-05-15 |
| AU2009207478B2 (en) | 2013-11-21 |
| CA2712959C (en) | 2015-06-23 |
| IL206808A (en) | 2015-08-31 |
| JP2011510055A (ja) | 2011-03-31 |
| US8916591B2 (en) | 2014-12-23 |
| EP2294065A1 (en) | 2011-03-16 |
| US20180244652A1 (en) | 2018-08-30 |
| EA201001197A1 (ru) | 2011-04-29 |
| JP5386508B2 (ja) | 2014-01-15 |
| BRPI0906495A2 (pt) | 2015-07-14 |
| ES2461799T3 (es) | 2014-05-21 |
| CA2712959A1 (en) | 2009-07-30 |
| US20200361905A1 (en) | 2020-11-19 |
| US20150099736A1 (en) | 2015-04-09 |
| EP2294065B1 (en) | 2014-03-19 |
| BRPI0906495B1 (pt) | 2020-11-10 |
| US20110021498A1 (en) | 2011-01-27 |
| CN101970424A (zh) | 2011-02-09 |
| ZA201005210B (en) | 2011-03-30 |
| EA021464B1 (ru) | 2015-06-30 |
| BRPI0906495A8 (pt) | 2015-10-06 |
| WO2009093012A1 (en) | 2009-07-30 |
| MX2010007525A (es) | 2010-08-18 |
| CN101970424B (zh) | 2013-06-12 |
| IL206808A0 (en) | 2010-12-30 |
| NZ586756A (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0906495B8 (pt) | compostos derivados de indolil-piridona e composição farmacêutica | |
| BRPI0720993B8 (pt) | usos de compostos análogos de ciclopamina | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| UY31084A1 (es) | Compuestos de azaindol para la inhibicion de b-secretasa | |
| BRPI0520870B8 (pt) | compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila | |
| CR9830A (es) | Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa | |
| CR20110169A (es) | Compuestos de pirrol | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| CR9244A (es) | AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA | |
| ATE542798T1 (de) | Organische verbindungen | |
| UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
| UY31083A1 (es) | Derivados de sulfoximinas para la inhibicion de b-secretasa | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| MY149180A (en) | Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof | |
| UY30387A1 (es) | Nuevos compuestos | |
| UY29360A1 (es) | Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones. | |
| PL2404901T3 (pl) | 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic | |
| BRPI0810719A8 (pt) | Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 | |
| UY30300A1 (es) | Compuestos triarílicos y sus derivados | |
| WO2011038234A3 (en) | Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions | |
| DK2190426T3 (da) | Griseofulvin-analoger til behandling af cancer ved hæmning af centrosomal clusterdannelse | |
| BRPI0507052A (pt) | inibidores de quìnase | |
| EA014959B3 (ru) | Ингибиторы глицинового переносчика-1 | |
| BR0312608A (pt) | Adjuvantes lìquidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2706 DE 16-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |